| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6863891 | EMD SERONO INC | Oligopeptide lyophilisate, their preparation and use |
Feb, 2014
(10 years ago) | |
| US7605121 | EMD SERONO INC | Oligopeptide lyophilisate, their preparation and use |
Feb, 2014
(10 years ago) | |
| US6319192 | EMD SERONO INC | Method for the treatment of fertility disorders |
Apr, 2019
(5 years ago) | |
Cetrotide is owned by Emd Serono Inc.
Cetrotide contains Cetrorelix Acetate.
Cetrotide has a total of 3 drug patents out of which 3 drug patents have expired.
Expired drug patents of Cetrotide are:
- US6863891
- US7605121
- US6319192
Cetrotide was authorised for market use on 11 August, 2000.
Cetrotide is available in powder;subcutaneous dosage forms.
Cetrotide can be used as prevention of premature lh surges in women undergoing controlled ovarian stimulation.
The generics of Cetrotide are possible to be released after 23 April, 2019.
Drugs and Companies using CETRORELIX ACETATE ingredient
Market Authorisation Date: 11 August, 2000
Treatment: Prevention of premature lh surges in women undergoing controlled ovarian stimulation
Dosage: POWDER;SUBCUTANEOUS
CETROTIDE family patents
